{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:27:38Z","timestamp":1760898458530,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017B030311015","2015A030313536"],"award-info":[{"award-number":["2017B030311015","2015A030313536"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Fund of Guangdong Province,","award":["A2017317"],"award-info":[{"award-number":["A2017317"]}]},{"name":"National Key R&D Program of China","award":["2017YFC1310200"],"award-info":[{"award-number":["2017YFC1310200"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671275","81501112"],"award-info":[{"award-number":["81671275","81501112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12883-018-1230-1","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T07:11:03Z","timestamp":1545894663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review"],"prefix":"10.1186","volume":"18","author":[{"given":"Piao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-4669","authenticated-orcid":false,"given":"Yuhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"issue":"Suppl 1","key":"1230_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011;26(Suppl 1):S1\u201358.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"1230_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11318330-000000000-00000","volume":"27","author":"LD Wood","year":"2010","unstructured":"Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging. 2010;27(4):295\u2013310.","journal-title":"Drugs Aging"},{"issue":"10","key":"1230_CR3","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","volume":"57","author":"K Kujawa","year":"2000","unstructured":"Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000;57(10):1461\u20133.","journal-title":"Arch Neurol"},{"issue":"12","key":"1230_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"2","key":"1230_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","volume":"45","author":"D Nyholm","year":"2006","unstructured":"Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Clin Pharmacokinet. 2006;45(2):109\u201336.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1230_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.mcna.2010.03.007","volume":"94","author":"T Limsuwan","year":"2010","unstructured":"Limsuwan T, Demoly P. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med Clin North Am. 2010;94(4):691\u2013710 x.","journal-title":"Med Clin North Am"},{"issue":"11","key":"1230_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2165\/11537810-000000000-00000","volume":"24","author":"S Perez-Lloret","year":"2010","unstructured":"Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. CNS Drugs. 2010;24(11):941\u201368.","journal-title":"CNS Drugs"},{"key":"1230_CR8","doi-asserted-by":"crossref","unstructured":"Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K, Gray R: Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008(2):Cd006564.","DOI":"10.1002\/14651858.CD006564.pub2"},{"issue":"9","key":"1230_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","volume":"6","author":"A Antonini","year":"2007","unstructured":"Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007;6(9):826\u20139.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1230_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2174\/156802608785161457","volume":"8","author":"T Kvernmo","year":"2008","unstructured":"Kvernmo T, Houben J, Sylte I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049\u201367.","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"1230_CR11","first-page":"319","volume":"53","author":"S Guimaraes","year":"2001","unstructured":"Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53(2):319\u201356.","journal-title":"Pharmacol Rev"},{"issue":"5\u20136","key":"1230_CR12","first-page":"1069","volume":"9","author":"JL Montastruc","year":"1987","unstructured":"Montastruc JL, Chamontin B, Rostin M, Rascol O, Valet P, Gaillard G, Tran MA, Van TT, Ader JL, Montastruc P. Experimental and clinical approaches to treatment of hypertension by dopamine receptor agonists. Clin Exp Hypertens A. 1987;9(5\u20136):1069\u201384.","journal-title":"Clin Exp Hypertens A"},{"issue":"1","key":"1230_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/j.1552-4604.1992.tb03788.x","volume":"32","author":"A Luchsinger","year":"1992","unstructured":"Luchsinger A, Velasco M, Urbina A, Morillo J, Romero E, Alvarez R, Pieretti OH. Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients. J Clin Pharmacol. 1992;32(1):55\u201360.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1230_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2165\/00003495-199346030-00005","volume":"46","author":"JL Montastruc","year":"1993","unstructured":"Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs. 1993;46(3):384\u201393.","journal-title":"Drugs"},{"issue":"8","key":"1230_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-016-0360-5","volume":"30","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret S, Rascol O. Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS drugs. 2016;30(8):703\u201317.","journal-title":"CNS drugs"},{"issue":"Suppl 1","key":"1230_CR16","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/BF00819559","volume":"239","author":"P Jenner","year":"1992","unstructured":"Jenner P. Parkinson's disease: pathological mechanisms and actions of piribedil. J Neurol. 1992;239(Suppl 1):S2\u20138.","journal-title":"J Neurol"},{"issue":"3","key":"1230_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40801-015-0028-3","volume":"2","author":"SA Hollingworth","year":"2015","unstructured":"Hollingworth SA, McGuire TM, Pache D, Eadie MJ. Dopamine agonists: time pattern of adverse effects reporting in Australia. Drugs -Rreal World Outcomes. 2015;2(3):199\u2013203.","journal-title":"Drugs -Rreal World Outcomes"},{"issue":"2\u20133","key":"1230_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0014-2999(98)00397-5","volume":"353","author":"S Lahlou","year":"1998","unstructured":"Lahlou S. Involvement of spinal dopamine receptors in mediation of the hypotensive and bradycardic effects of systemic quinpirole in anaesthetised rats. Eur J Pharmacol. 1998;353(2\u20133):227\u201337.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"1230_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1440-1681.2004.04095.x","volume":"31","author":"JS Polakowski","year":"2004","unstructured":"Polakowski JS, Segreti JA, Cox BF, Hsieh GC, Kolasa T, Moreland RB, Brioni JD. Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin Exp Pharmacol Physiol. 2004;31(12):837\u201341.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"1230_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000139365","volume":"51","author":"FY Chueh","year":"1995","unstructured":"Chueh FY, Hsieh MT, Chen CF, Lin MT. DL-tetrahydropalmatine-produced hypotension and bradycardia in rats through the inhibition of central nervous dopaminergic mechanisms. Pharmacology. 1995;51(4):237\u201344.","journal-title":"Pharmacology"},{"issue":"4","key":"1230_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/01.HYP.8.4.298","volume":"8","author":"CE McCoy","year":"1986","unstructured":"McCoy CE, Douglas FL, Goldberg LI. Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats. Hypertension. 1986;8(4):298\u2013302.","journal-title":"Hypertension"},{"issue":"11","key":"1230_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/0024-3205(82)90078-9","volume":"31","author":"I Cavero","year":"1982","unstructured":"Cavero I, Massingham R, Lefevere-Borg F. Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part II: sites and mechanisms of action of dopamine receptor agonists. Life Sci. 1982;31(11):1059\u201369.","journal-title":"Life Sci"},{"issue":"3","key":"1230_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/157015908785777193","volume":"6","author":"ER Samuels","year":"2008","unstructured":"Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol. 2008;6(3):254\u201385.","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"1230_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","volume":"128","author":"MJ Millan","year":"2010","unstructured":"Millan MJ. From the cell to the clinic: a comparative review of the partial D(2)\/D(3) receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Ther. 2010;128(2):229\u201373.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1230_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1527-3458.2005.tb00047.x","volume":"11","author":"A Pertovaara","year":"2005","unstructured":"Pertovaara A, Haapalinna A, Sirvio J, Virtanen R. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev. 2005;11(3):273\u201388.","journal-title":"CNS Drug Rev"},{"issue":"1 Pt 2","key":"1230_CR26","first-page":"S14","volume":"18","author":"MB Murphy","year":"1990","unstructured":"Murphy MB, Elliott WJ. Dopamine and dopamine receptor agonists in cardiovascular therapy. Crit Care Med. 1990;18(1 Pt 2):S14\u20138.","journal-title":"Crit Care Med"},{"issue":"4","key":"1230_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","volume":"66","author":"MM Pinter","year":"1999","unstructured":"Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66(4):436\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1230_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/j.1552-4604.1997.tb04330.x","volume":"37","author":"CE Wright","year":"1997","unstructured":"Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 1997;37(6):520\u20135.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1230_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.14740\/jocmr2541e","volume":"8","author":"R Vecchis De","year":"2016","unstructured":"De Vecchis R, Cantatrione C, Mazzei D, Baldi C, Di Maio M. Non-ergot dopamine agonists do not increase the risk of heart failure in Parkinson's disease patients: a meta-analysis of randomized controlled trials. J Clin Med Res. 2016;8(6):449\u201360.","journal-title":"J Clin Med Res"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1230-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-018-1230-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1230-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T13:16:27Z","timestamp":1694524587000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-018-1230-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1186\/s12883-018-1230-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"12 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"221"}}